Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Avai Bio (AVAI) EBITDA (2018 - 2024)

Avai Bio's EBITDA history spans 6 years, with the latest figure at $507711.0 for Q1 2024.

  • For Q1 2024, EBITDA rose 188.62% year-over-year to $507711.0; the TTM value through Mar 2024 reached -$2.1 million, down 510.0%, while the annual FY2025 figure was -$1.1 million, 46.34% up from the prior year.
  • EBITDA for Q1 2024 was $507711.0 at Avai Bio, up from -$1.8 million in the prior quarter.
  • Across five years, EBITDA topped out at $507711.0 in Q1 2024 and bottomed at -$1.8 million in Q4 2023.
  • The 4-year median for EBITDA is $45005.0 (2020), against an average of -$198412.2.
  • The largest YoY upside for EBITDA was 21950.18% in 2020 against a maximum downside of 1866.77% in 2020.
  • A 4-year view of EBITDA shows it stood at $431541.0 in 2020, then tumbled by 74.4% to $110471.0 in 2022, then plummeted by 1752.06% to -$1.8 million in 2023, then soared by 127.82% to $507711.0 in 2024.
  • Per Business Quant, the three most recent readings for AVAI's EBITDA are $507711.0 (Q1 2024), -$1.8 million (Q4 2023), and -$399621.0 (Q3 2023).